Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.
Prendiville, Joseph A
Jayson, Gordon C
Fox, Brian W
Pettit, G R
Stern, Peter L
AffiliationCancer Research Campaign Department of Immunology, Christie Hospital, Paterson Institute for Cancer Research, Manchester, UK.
MetadataShow full item record
AbstractBryostatin 1 is a protein kinase C activator that inhibits growth of tumour cells and activates lymphocytes in vitro, properties that have encouraged its use in phase 1 clinical studies as an anticancer agent. We investigated interleukin-2(IL-2)-induced proliferation and lymphokine-activated killer (LAK) cell activity in peripheral blood mononuclear cells (PBMC) from cancer patients receiving Bryostatin intravenously. After Bryostatin administration both LAK generation and proliferation were enhanced when patients' PBMC were stimulated with IL-2 in vitro. However, when normal donors' PBMC were cultured in vitro in the presence Bryostatin and IL-2, LAK induction was inhibited while IL-2-driven proliferation was increased. These effects were also seen following only 2 h exposure to Bryostatin and could be elicited by conditioned medium from Bryostatin-pretreated cells. Neither IL-4 nor interferon gamma was detected in the conditioned medium. Bryostatin in vitro was found to increase expression of IL-2 receptors on CD4+, CD8+ and CD56+ cells and augment the proportion of CD8+ cells in conjunction with IL-2. We conclude that Bryostatin in combination with IL-2 in vitro enhances proliferation and IL-2 receptor expression on lymphocytes, favouring CD8+ cells while suppressing the generation of LAK activity. Intravenous administration of Bryostatin increases the potential of IL-2 to induce proliferation and LAK activity in lymphocytes which, taken together with its putative direct antitumour effect, makes Bryostatin an interesting candidate for clinical trials in combination with IL-2.
CitationImmunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. 1994, 39 (4):223-30 Cancer Immunol. Immunother.
JournalCancer Immunology, Immunotherapy
- A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
- Authors: Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S
- Issue date: 1995 Aug
- Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
- Authors: Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD
- Issue date: 1998 Mar
- Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
- Authors: Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Beroukas C, Stathopoulos GP, Papamichail M
- Issue date: 1995 Oct 1
- The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity.
- Authors: Tilden AB, Kraft AS
- Issue date: 1991 Apr
- Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).
- Authors: Shirasaka T, Kawase I, Okada M, Kitahara M, Ikeda T, Komuta K, Hosoe S, Yokota S, Masuno T, Kishimoto S
- Issue date: 1989